c
栏目内容Column content
c
联系我们Contact us
石家庄佐泰医药科技有限公司
地址:石家庄市桥西区中山路108号华润万象城D座2117
传  真:0311-87767676
联系电话: 0311-88889998
邮  箱: zuotai_vip@163.com 
网  址: www.sjzztyy.cn
FDA行业指南:ANDA申报---拒绝受理杂质限度缺乏适当论

2016-06-26 09:00:31 作者:出处:

FDA Submissions — Refuse to Receive for Lack of Proper Justification of Impurity Limits

Guidance for Industry

DRAFT GUIDANCE

行业指南:ANDA申报---拒绝受理杂质限度缺乏适当论述的申报(草案)

This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.

本指南仅供征求意见。关于本草案的建议和意见请在联邦注册上的通知公布后60天内,电子提交至上述网站。书面意见提交给上述地址。所有建议均应标明联邦注册上的档案编号。

For questions regarding this draft document contact (CDER) Elizabeth Giaquinto 240-402-7930.

U.S. Department of Health and Human Services

Food and Drug Administration

Center for Drug Evaluation and Research (CDER)

September 2014

Generic Drugs


 

ANDA Submissions —

Refuse to Receive for

Lack of Proper Justification of Impurity Limits

Guidance for Industry

Additional copies are available from:

Office of Communications

Division of Drug Information, WO51, Room 2201

Center for Drug Evaluation and Research

Food and Drug Administration

10903 New Hampshire Ave., Silver Spring, MD 20993

Phone: 301-796-3400; Fax: 301-847-8714

druginfo@fda.hhs.gov

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

U.S. Department of Health and Human Services

Food and Drug Administration

Center for Drug Evaluation and Research (CDER)

September 2014

Generic Drugs


 

TABLE OF CONTENTS

I. INTRODUCTION概述

II. BACKGROUND背景

III. JUSTIFYING IMPURITY LIMITS IN DRUG SUBSTANCES AND PRODUCTS. 原料药和制剂中杂质限度论述

A. Refusal to Receive for Lack of Impurities Information 因为缺少杂质资料而拒绝受理

B. Providing Proper Justification for Impurity Limits如何提交适当的杂质限度论述

 


 

ANDA Submissions – Refuse to Receive for Lack of Proper Justification of Impurity Limits

Guidance for Industry[1]

行业指南:ANDA申报---拒绝受理杂质限度缺乏适当论述的申报

佐泰医药公司地址:石家庄市桥西区中山路108号华润万象城D座2117
Copyright@2016 石家庄佐泰医药科技有限公司 版权所有  技术支持:金色方向  冀ICP备16004518号-2
热线电话
0311-88889998